Aktiviteter pr. år
Projektdetaljer
Beskrivelse
Immunotherapy (IO) is the new standard of care for many patients with advanced Non-Small Cell Lung Cancer (aNSCLC), yet only around 30-50% of treated patients benefit from IO in the long term. Programmed Death-Ligand 1 (PD-L1) remains the only biomarker used to predict patient outcome to IO, though its efficacy is limited. Other potential biomarkers have been identified, yet not validated in prospective randomized clinical trials, providing only partial evidence. Due to the dynamic complexity of the immune system-tumour microenvironment, its interaction with the host and patient behaviour, it?s unlikely for a single biomarker to accurately predict patient outcome. Artificial Intelligence (AI) and machine learning (ML) frameworks, that synthetize and correlate information from multiple sources, are essential to develop powerful decision-making tools able to deal with this highly complex context and provide individualized predictions to improve patient outcomes reducing the economic burden of health care systems in NSCLC.
The aim of the I3LUNG project is to develop such AI-based tools to assist in improving survival and quality of life, preventing undue toxicity, and reducing treatment costs. I3LUNG adopts a two-pronged approach: setting up a transnational platform of available data from 2000 patients in order to validate the AI models, and generating a multi-omics prospective data collection in 200 NSCLC patients integrating diverse -omic information then validate its usefulness in leading IO therapeutic decisions. A psychological study will help in defining the impact of AI-guided decisions on patients, eliciting their preference, and physicians comparing AI with Human Intuition. The final goal is the construction of a novel integrated AI-assisted Data Storage and Elaboration Platform backed up by Trustworthy Explainable AI methodology, ensuring its accessibility and ease of use by healthcare providers and patients alike.
The aim of the I3LUNG project is to develop such AI-based tools to assist in improving survival and quality of life, preventing undue toxicity, and reducing treatment costs. I3LUNG adopts a two-pronged approach: setting up a transnational platform of available data from 2000 patients in order to validate the AI models, and generating a multi-omics prospective data collection in 200 NSCLC patients integrating diverse -omic information then validate its usefulness in leading IO therapeutic decisions. A psychological study will help in defining the impact of AI-guided decisions on patients, eliciting their preference, and physicians comparing AI with Human Intuition. The final goal is the construction of a novel integrated AI-assisted Data Storage and Elaboration Platform backed up by Trustworthy Explainable AI methodology, ensuring its accessibility and ease of use by healthcare providers and patients alike.
Kort titel | Horizon Europe I3LUNG |
---|---|
Akronym | Horizon Europe I3LUNG |
Status | Igangværende |
Effektiv start/slut dato | 01/04/2022 → 31/03/2027 |
Samarbejdspartnere
- IRCCS Fondazione Istituto Nazionale per lo studio e la cura dei tumori - Milano (Projektpartner) (leder)
- Polytechnic University of Milan (Projektpartner)
- IRCCS Istituto di ricerche farmacologiche Mario Negri - Milano, Bergamo, Ranica (Projektpartner)
- IRCCS Istituto Europeo di Oncologia - Milano (Projektpartner)
- ML Cube S.r.l. (Projektpartner)
- LungenClinic Grosshansdorf GmbH (Projektpartner)
- UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF (Projektpartner)
- FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON (VHIO) (Projektpartner)
- Medica Scientia Innovation Research (Projektpartner)
- 4th Oncology Dept, Metropolitan Hospital (Projektpartner)
- Shaare Zedek Medical Center (Projektpartner)
- KU Leuven (Projektpartner)
- IHE, INSTITUTET FOR HALSO- OCH SJUKVARDSEKONOMI AKTIEBOLAG (Projektpartner)
- The University of Chicago (Projektpartner)
- Lung Cancer Europe (Projektpartner)
Finansiering
- European Commission: 74.431.941,17 kr.
FN's verdensmål
I 2015 blev FN-landene enige om 17 verdensmål til at bekæmpe fattigdom, beskytte planeten og sikre velstand for alle. Dette projekt bidrager til følgende verdensmål:
Fingerprint
Udforsk forskningsemnerne, som dette projekt berører. Disse etiketter er oprettet på grundlag af de underliggende bevillinger/legater. Sammen danner de et unikt fingerprint.
Aktiviteter
-
Horizon Europe I3LUNG Project Annual Meeting 2023
Kosta, S. (Deltager)
30 jun. 2023 → 1 jul. 2023Aktivitet: Deltagelse i faglig begivenhed › Organisering af eller deltagelse i workshop, kursus, seminar, udstilling eller lignende
-
2023 IEEE International Conference on Metaverse Computing, Networking and Applications
Ferens Michalek, M. J. (Deltager) & Zanitti, M. (Deltager)
26 jun. 2023 → 28 jun. 2023Aktivitet: Deltagelse i faglig begivenhed › Organisering af eller deltagelse i konference
-
Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review
Prelaj, A., Miskovic, V., Zanitti, M., Trovo, F., Genova, C., Viscardi, G., Rebuzzi, S. E., Mazzeo, L., Provenzano, L., Kosta, S., Favali, M., Spagnoletti, A., Castelo-Branco, L., Dolezal, J., Pearson, A. T., Lo Russo, G., Proto, C., Ganzinelli, M., Giani, C. & Ambrosini, E. & 10 flere, , jan. 2024, I: Annals of Oncology. 35, 1, s. 29-65 37 s.Publikation: Bidrag til tidsskrift › Review (oversigtsartikel) › peer review
55 Citationer (Scopus) -
MetaLung: Towards a Secure Architecture for Lung Cancer Patient Care on the Metaverse
Zanitti, M., Ferens, M., Ferrarin, A., Trovò, F., Miskovic, V., Prelaj, A., Shen, M. & Kosta, S., 6 okt. 2023, Proceedings - 2023 IEEE International Conference on Metaverse Computing, Networking and Applications, MetaCom 2023. IEEE (Institute of Electrical and Electronics Engineers), s. 201-208 8 s. 10271813Publikation: Bidrag til bog/antologi/rapport/konference proceeding › Konferenceartikel i proceeding › Forskning › peer review
3 Citationer (Scopus)
Presse/medier
-
Integrative science, Intelligent data platform for Individualized LUNG cancer care with Immunotherapy
06/09/2022
1 element af Mediedækning
Presse/medie